Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-02FDA Approved: LEVETIRACETAM — Original Application (Baxter Healthcare Corporation)
FDA approved Baxter Healthcare Corporation's original-application generic levetiracetam (ANDA 217059) for seizure disorders, establishing a …
-
FDA approval · 2023-09-27FDA Approved: TOPIRAMATE — Original Application (Aurobindo Pharma Limited)
FDA approves the Original Application for Topiramate (generic) by Aurobindo Pharma Limited. Topiramate is used as an anticonvulsant for epil…
-
FDA approval · 2023-09-26FDA Approved: LEVETIRACETAM — Supplemental Application (Method Pharmaceuticals, LLC)
The FDA approved a supplemental application for levetiracetam by Method Pharmaceuticals, LLC.
-
FDA approval · 2023-09-26FDA Approved: DIVALPROEX SODIUM — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for divalproex sodium, providing a generic option for this anticonvulsant/mood stabilizer…
-
CLINICAL_TRIALS trial_result · 2023-09-22Clinical Trial Update: Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy [Phase 2]
Phase 2 trial investigating add-on low-dose fenfluramine in Lennox-Gastaut epilepsy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-09-19FDA Approved: PHENYTOIN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for phenytoin (Sun Pharmaceutical Industries, Inc.) under an ANDA, indicating an update to label…
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy [Phase 2]
Phase 2 pharmacokinetic study of an oral suspension of perampanel as adjunctive therapy in pediatric epilepsy subjects has completed with re…
-
FDA approval · 2023-09-14FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for FINTEPLA (fenfluramine) from UCB, Inc.; the approval updates the drug's labeling and/or indicati…
-
FDA approval · 2023-09-13FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) filed by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-09-11FDA Approved: CLOBAZAM — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for CLOBAZAM (clobazam) from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2023-09-11FDA Approved: ACETAZOLAMIDE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s original application for acetazolamide (generic).
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: High Frequency Oscillation in Pediatric Epilepsy Surgery [NA]
A completed clinical trial update on high frequency oscillation in pediatric epilepsy surgery; results posted in 2023.
-
FDA approval · 2023-08-31FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc.
-
FDA approval · 2023-08-31FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Keppra (levetiracetam) from UCB, Inc., indicating an approved modification or expansion rela…
-
FDA approval · 2023-08-31FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA indicates a Supplemental Application for Levetiracetam submitted by Prasco Laboratories; this represents an additional regulatory action…
-
FDA approval · 2023-08-25FDA Approved: ACETAZOLAMIDE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for acetazolamide sodium filed by Mylan Institutional LLC, approving the salt form of acetazolamide …
-
FDA approval · 2023-08-17FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Keppra (levetiracetam) from UCB, Inc. The approval indicates an update to the drug's labeling or…
-
FDA approval · 2023-08-17FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Keppra (levetiracetam) submitted by UCB, Inc.
-
FDA approval · 2023-08-17FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA XR (levetiracetam) from UCB, Inc.
-
FDA approval · 2023-08-16FDA Approved: ACETAZOLAMIDE — Supplemental Application (Eywa Pharma Inc)
The FDA approved Eywa Pharma Inc's supplemental application for acetazolamide, enabling continued marketing of a generic acetazolamide produ…
-
FDA approval · 2023-08-15FDA Approved: TOPIRAMATE — Original Application (Ajanta Pharma USA Inc.)
The FDA approved Ajanta Pharma USA Inc.'s generic Topiramate through an Original Application (ANDA 215663). This approval provides a generic…
-
FDA approval · 2023-08-08FDA Approved: OXCARBAZEPINE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
FDA approved a supplemental application for oxcarbazepine by Breckenridge Pharmaceutical, Inc.
-
FDA approval · 2023-08-07FDA Approved: TOPIRAMATE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Topiramate submitted by Zydus Lifesciences Limited.
-
FDA approval · 2023-08-07FDA Approved: GABAPENTIN — Supplemental Application (Ajenat Pharmaceuticals LLC)
FDA approves a supplemental application for Gabapentin submitted by Ajenat Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy [Phase 4]
Phase 4 trial update assessing the improvement in cognitive function with lacosamide and levetiracetam in patients with Alzheimer's disease …